Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Ophthalmology

Precision Medicine: Treatments and Clinical Trials

At a Glance

The treatment landscape for Leber Congenital Amaurosis (LCA) includes Luxturna, an FDA-approved gene therapy for the RPE65 mutation, alongside clinical trials using gene augmentation and CRISPR for other types. Standard supportive care and low-vision aids remain essential for managing the condition.

For decades, a diagnosis of Leber Congenital Amaurosis (LCA) meant there were no active treatments. Today, we are in a historic era of “precision medicine,” where the treatment is designed specifically for your child’s exact genetic mutation. This has created a two-track landscape: one FDA-approved therapy and a wide range of investigational clinical trials.

The First Approved Treatment: Luxturna

Voretigene neparvovec (brand name Luxturna) is the first and currently only FDA-approved gene therapy for an inherited retinal disease [1]. It is specifically for the RPE65 type of LCA [2].

Eligibility Criteria

To qualify for Luxturna, a child must meet three primary requirements:

  1. Genetic Confirmation: They must have biallelic mutations in the RPE65 gene, meaning they have two disease-causing mutations (one from each parent) [3][4].
  2. Viable Retinal Cells: The treatment works by “rebooting” surviving cells. Doctors use scans like OCT to ensure there are still enough functional photoreceptors at the time of the procedure to benefit from the therapy [1][5].
  3. Age Requirement: The FDA has approved this therapy for patients aged 12 months and older, as the eye needs to have grown sufficiently before the procedure.

The Procedure

It is important to know that Luxturna is not a pill or an eye drop; it is administered via a specialized surgical procedure called a subretinal injection, which is performed under general anesthesia [6]. As with any eye surgery, there are risks, such as retinal tears, cataracts, or increased intraocular pressure (and potential chorioretinal atrophy associated with inflammation), which you should discuss thoroughly with your surgical team [6][7].

Investigational Treatments & Clinical Trials

For children with other types of LCA, researchers are testing three main “next-generation” strategies.

1. Gene Augmentation (Replacement)

Similar to Luxturna, this involves using a tiny, harmless virus to “deliver” a healthy copy of the gene into the retinal cells [8].

  • GUCY2D-LCA: A trial for the gene therapy ATSN-101 has shown significant, sustained improvements in retinal sensitivity 12 months after treatment with no serious drug-related side effects [9]. This is particularly promising because many children with GUCY2D mutations have high “cell viability” despite low vision [10].

2. Antisense Oligonucleotides (ASOs)

Instead of replacing the whole gene, ASOs are small, injectable “genetic patches” that hide a mistake in the DNA, allowing the cell to skip over the error and make functional protein [11].

  • CEP290-LCA: The ASO candidate sepofarsen previously showed early improvements in visual function, though its Phase 3 trial was ultimately halted [12]. This serves as an important historical example of how ASOs work, even as research shifts to newer candidates and approaches for this gene [12][13].

3. Gene Editing (CRISPR)

This technology directly “edits” the child’s DNA to fix the mutation [11].

  • CEP290-LCA: A first-in-human trial for EDIT-101 used CRISPR to remove a specific mutation in the CEP290 gene [14]. While early results showed a favorable safety profile and improved photoreceptor function in some participants, development was paused to seek partners for further funding. These early trials paved the way for the next generation of in vivo gene editing [14][15].

Standard of Care (Supportive Management)

If a gene-specific treatment is not yet available, management focuses on maximizing your child’s quality of life and development [16]:

  • Early Intervention: Specialized educational support and occupational therapy help children hit developmental milestones [17].
  • Low-Vision Aids: Tools like high-contrast materials, specialized lighting, and magnification can help a child use their remaining functional vision effectively.
  • Regular Monitoring: Ongoing exams are necessary to monitor for complications and to ensure your child is ready if a new treatment or trial becomes available [18].

Vetting a Treatment Center

Gene therapy is a highly specialized field. When evaluating a center, you should ask about their experience with multidisciplinary care [16]. A top-tier center should have not only expert surgeons but also genetic counselors to explain reports and low-vision specialists to support your child’s daily life [19]. It is also vital that they use advanced testing, like Full-field Stimulus Testing (FST), which is often a better measure of light sensitivity than standard eye charts for children with LCA [20][21].

Common questions in this guide

Does my child qualify for Luxturna gene therapy?
To qualify for Luxturna, a child must have confirmed biallelic mutations in the RPE65 gene and enough viable retinal cells. They must also be at least 12 months old so the eye has grown sufficiently for the surgical procedure.
How is Luxturna administered?
Luxturna is not an eye drop or pill. It is administered through a specialized surgical procedure called a subretinal injection, which is performed by an expert eye surgeon while your child is under general anesthesia.
What other gene therapies are being tested for LCA in clinical trials?
Researchers are testing several next-generation strategies for other genetic forms of LCA. These include gene augmentation for GUCY2D mutations, as well as antisense oligonucleotides (ASOs) and CRISPR gene editing for CEP290 mutations.
What are the standard treatments for LCA if gene therapy isn't an option?
If a gene-specific treatment is not available, care focuses on maximizing your child's quality of life. This includes early educational intervention, occupational therapy, and low-vision aids like magnification and specialized lighting to utilize their remaining functional vision.
Why might the doctor recommend Full-field Stimulus Testing (FST)?
FST is an advanced vision test that measures light sensitivity better than standard eye charts for children with LCA. It is often used by specialized centers to establish a baseline of a child's vision before starting any potential treatments or trials.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Does my child have biallelic RPE65 mutations, and does their OCT scan show enough 'viable retinal cells' to qualify for Luxturna?
  2. 2.What is the difference between gene augmentation, ASOs, and CRISPR for my child's specific genetic mutation?
  3. 3.Can you perform Full-field Stimulus Testing (FST) to establish a baseline of my child's current light sensitivity?
  4. 4.How many gene therapy procedures has this center performed specifically for pediatric LCA patients?
  5. 5.If my child joins a clinical trial, what is the 'washout period' or potential impact on their eligibility for future treatments?
  6. 6.Does the care team include a low-vision specialist who can help us with functional vision aids right now?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (21)
  1. 1

    Voretigene Neparvovec: A Review in RPE65 Mutation-Associated Inherited Retinal Dystrophy.

    Kang C, Scott LJ

    Molecular diagnosis & therapy 2020; (24(4)):487-495 doi:10.1007/s40291-020-00475-6.

    PMID: 32535767
  2. 2

    RPE65 Mutation-associated Inherited Retinal Disease and Gene Therapies.

    Camp DA, Falabella P, Ciulla TA

    International ophthalmology clinics 2021; (61(4)):125-132 doi:10.1097/IIO.0000000000000381.

    PMID: 34584049
  3. 3

    Voretigene Neparvovec for the Treatment of RPE65-associated Retinal Dystrophy: Consensus and Recommendations from the Korea RPE65-IRD Consensus Paper Committee.

    Han J, Joo K, Kim US, et al.

    Korean journal of ophthalmology : KJO 2023; (37(2)):166-186 doi:10.3341/kjo.2023.0008.

    PMID: 36950921
  4. 4

    Inherited Retinal Diseases Due to RPE65 Variants: From Genetic Diagnostic Management to Therapy.

    Aoun M, Passerini I, Chiurazzi P, et al.

    International journal of molecular sciences 2021; (22(13)) doi:10.3390/ijms22137207.

    PMID: 34281261
  5. 5

    Gene Therapy for Inherited Retinal Disease: Long-Term Durability of Effect.

    Leroy BP, Fischer MD, Flannery JG, et al.

    Ophthalmic research 2023; (66(1)):179-196 doi:10.1159/000526317.

    PMID: 36103843
  6. 6

    The effect of human gene therapy for RPE65-associated Leber's congenital amaurosis on visual function: a systematic review and meta-analysis.

    Wang X, Yu C, Tzekov RT, et al.

    Orphanet journal of rare diseases 2020; (15(1)):49 doi:10.1186/s13023-020-1304-1.

    PMID: 32059734
  7. 7

    Gene therapy outcomes in young patients with RPE65-retinal degeneration.

    Stephenson KAJ, Alsalamah AK, Tumber A, et al.

    Canadian journal of ophthalmology. Journal canadien d'ophtalmologie 2026; (61(3)):685-692 doi:10.1016/j.jcjo.2026.01.016.

    PMID: 41679721
  8. 8

    An Update on Gene Therapy for Inherited Retinal Dystrophy: Experience in Leber Congenital Amaurosis Clinical Trials.

    Chiu W, Lin TY, Chang YC, et al.

    International journal of molecular sciences 2021; (22(9)) doi:10.3390/ijms22094534.

    PMID: 33926102
  9. 9

    Safety and efficacy of ATSN-101 in patients with Leber congenital amaurosis caused by biallelic mutations in GUCY2D: a phase 1/2, multicentre, open-label, unilateral dose escalation study.

    Yang P, Pardon LP, Ho AC, et al.

    Lancet (London, England) 2024; (404(10456)):962-970 doi:10.1016/S0140-6736(24)01447-8.

    PMID: 39244273
  10. 10

    GUCY2D-Associated Leber Congenital Amaurosis: A Retrospective Natural History Study in Preparation for Trials of Novel Therapies.

    Bouzia Z, Georgiou M, Hull S, et al.

    American journal of ophthalmology 2020; (210()):59-70 doi:10.1016/j.ajo.2019.10.019.

    PMID: 31704230
  11. 11

    The advancements in precision medicine for Leber congenital amaurosis: Breakthroughs from genetic diagnosis to therapy.

    Zhang P, Xu Z

    Survey of ophthalmology 2025; (70(6)):1205-1219 doi:10.1016/j.survophthal.2025.04.005.

    PMID: 40311816
  12. 12

    Intravitreal antisense oligonucleotide sepofarsen in Leber congenital amaurosis type 10: a phase 1b/2 trial.

    Russell SR, Drack AV, Cideciyan AV, et al.

    Nature medicine 2022; (28(5)):1014-1021 doi:10.1038/s41591-022-01755-w.

    PMID: 35379979
  13. 13

    Durable vision improvement after a single treatment with antisense oligonucleotide sepofarsen: a case report.

    Cideciyan AV, Jacobson SG, Ho AC, et al.

    Nature medicine 2021; (27(5)):785-789 doi:10.1038/s41591-021-01297-7.

    PMID: 33795869
  14. 14

    Gene Editing for CEP290-Associated Retinal Degeneration.

    Pierce EA, Aleman TS, Jayasundera KT, et al.

    The New England journal of medicine 2024; (390(21)):1972-1984 doi:10.1056/NEJMoa2309915.

    PMID: 38709228
  15. 15

    Toward the Treatment of Inherited Diseases of the Retina Using CRISPR-Based Gene Editing.

    Hernández-Juárez J, Rodríguez-Uribe G, Borooah S

    Frontiers in medicine 2021; (8()):698521 doi:10.3389/fmed.2021.698521.

    PMID: 34660621
  16. 16

    Leber congenital amaurosis as an initial manifestation in a Chinese patient with thiamine-responsive megaloblastic anemia syndrome.

    Wu S, Yuan Z, Sun Z, et al.

    American journal of medical genetics. Part A 2022; (188(3)):948-952 doi:10.1002/ajmg.a.62582.

    PMID: 34821467
  17. 17

    Early onset retinal dystrophies: clinical clues to diagnosis for pediatricians.

    Suppiej A, Marino S, Reffo ME, et al.

    Italian journal of pediatrics 2019; (45(1)):168 doi:10.1186/s13052-019-0760-5.

    PMID: 31864384
  18. 18

    Clinical Characterization, Natural History, and Detailed Phenotyping of NMNAT1-Associated Leber Congenital Amaurosis.

    Lee YJ, Jeong HC, Kim JH, Jo DH

    American journal of ophthalmology 2025; (271()):396-406 doi:10.1016/j.ajo.2024.12.016.

    PMID: 39710161
  19. 19

    Phenotypic and Genetic Heterogeneity of a Pakistani Cohort of 15 Consanguineous Families Segregating Variants in Leber Congenital Amaurosis-Associated Genes.

    Akhtar Z, Altaf S, Li Y, et al.

    Genes 2024; (15(12)) doi:10.3390/genes15121646.

    PMID: 39766915
  20. 20

    Outcome Measures for Clinical Trials of Leber Congenital Amaurosis Caused by the Intronic Mutation in the CEP290 Gene.

    Jacobson SG, Cideciyan AV, Sumaroka A, et al.

    Investigative ophthalmology & visual science 2017; (58(5)):2609-2622 doi:10.1167/iovs.17-21560.

    PMID: 28510626
  21. 21

    Full-field stimulus testing: Role in the clinic and as an outcome measure in clinical trials of severe childhood retinal disease.

    Roman AJ, Cideciyan AV, Wu V, et al.

    Progress in retinal and eye research 2022; (87()):101000 doi:10.1016/j.preteyeres.2021.101000.

    PMID: 34464742

This page provides educational information about treatments and clinical trials for Leber Congenital Amaurosis (LCA). It is not a substitute for professional medical advice; always consult your child's ophthalmologist or genetic counselor regarding specific therapies.

Get notified when new evidence is published on Leber congenital amaurosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.